Surgical Techniques Compared for ThuLEP for Benign Prostatic Hyperplasia
By Elana Gotkine HealthDay Reporter
TUESDAY, Aug. 6, 2024 -- For patients undergoing Thulium laser enucleation of the prostate (ThuLEP) for benign prostatic hyperplasia (BPH), there are no significant differences in intraoperative and postoperative complications or in functional outcomes at three months for distinct surgical techniques, according to a study published online July 22 in the World Journal of Urology.
Francesco Cantiello, M.D., Ph.D., from the Magna Graecia University of Catanzaro in Italy, and colleagues conducted a retrospective analysis of patients undergoing ThuLEP for BPH between January 2019 and January 2024. Patients undergoing en-bloc, three-lobe, and two-lobe techniques were propensity score-matched; after matching, 213 patients were included in the analysis.
The researchers found that the en-bloc and two-lobe groups had significantly shorter enucleation, laser enucleation, morcellation, and operative times and total energy delivered compared with the three-lobe group in an intraoperative analysis. In terms of intraoperative and postoperative complications, there were no significant differences among the groups. At three-month follow-up, no significant differences were seen among the groups in functional outcomes.
"While the en-bloc and two-lobe techniques may offer efficiency benefits and could be considered safe alternatives in ThuLEP procedures, the reduction in laser enucleation time and energy delivered did not necessarily translate into improvements in postoperative storage symptoms or other functional outcomes," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
ASCO: Durvalumab Plus FLOT Beneficial for Resectable Gastric, GE Junction Cancer
THURSDAY, June 5, 2025 -- For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel...
Endolymphatic Sac Decompression Effective for Vertigo, Migraine
WEDNESDAY, May 28, 2025 -- For Meniere disease (MD) patients with migraine, endolymphatic sac decompression (ELSD) is effective, providing postoperative relief of vertigo and...
One-Week Radiotherapy for Breast Cancer Safe, Effective Up to 10 Years
TUESDAY, May 27, 2025 -- A five-fraction, one-week schedule of adjuvant breast radiotherapy is as safe and effective as a standard three-week schedule for patients with invasive...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.